Xenitra Secures AU$5 Million Specialised Medical Nutrition Agreement
Xenitra Limited (ASX: XEN) has strengthened its healthcare growth pipeline after its Hong Kong Fukang subsidiary entered a three-year Framework Purchase Agreement with JOY CHARM LIMITED. The agreement establishes a target aggregate procurement value of AU$5 million for Food for Special Medical Purposes (FSMP) products between 12 August 2026 and 12 August 2029.
The agreement expands Fukang’s operations beyond conventional over-the-counter medicines into specialised medical nutrition, while using its existing sourcing, regulatory and logistics infrastructure. Xenitra said the arrangement follows its recently announced AU$12 million Kangsheng pharmaceutical procurement agreement. Fukang also recorded July sales of more than AU$450,000 following its acquisition and integration. Importantly, the AU$5 million figure represents a procurement target rather than a guaranteed minimum purchase commitment. Under individual purchase orders, 20% is payable within seven days after execution and invoicing, with the remaining 80% payable after required shipment documentation is received.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Xenitra Secures AU$5 Million Specialised Medical Nutrition Agreement
Xenitra Limited (ASX: XEN) has strengthened its healthcare growth pipeline after its Hong Kong Fukang subsidiary entered a three-year Framework Purchase Agreement with JOY CHARM LIMITED. The agreement establishes a target aggregate procurement value of AU$5 million for Food for Special Medical Purposes (FSMP) products between 12 August 2026 and 12 August 2029.
The agreement expands Fukang’s operations beyond conventional over-the-counter medicines into specialised medical nutrition, while using its existing sourcing, regulatory and logistics infrastructure. Xenitra said the arrangement follows its recently announced AU$12 million Kangsheng pharmaceutical procurement agreement. Fukang also recorded July sales of more than AU$450,000 following its acquisition and integration. Importantly, the AU$5 million figure represents a procurement target rather than a guaranteed minimum purchase commitment. Under individual purchase orders, 20% is payable within seven days after execution and invoicing, with the remaining 80% payable after required shipment documentation is received.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au